Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Psychiatry ; 2024: 7630713, 2024.
Article in English | MEDLINE | ID: mdl-38633733

ABSTRACT

Cotard syndrome is a rare presentation where patients present with nihilistic thoughts of dying or already being dead. These delusions manifest from either a medical or psychiatric etiology and can be difficult to treat. Recently Couto and Gonçalves purposed that treatment should include an atypical antipsychotic alone or in combination with either a mood stabilizer or antidepressant. Here the authors advocate for a more specific but well-known psychotropic regimen, namely the combination of olanzapine and fluoxetine. We conducted a literature review and of 246 papers identified, only three reported using a combination of fluoxetine and olanzapine with many of them having limited or confounding information that make it difficult for us to comment on the historically efficacy of this medication combination. Therefore, the authors provide two case examples of patients being treated successfully with olanzapine and fluoxetine. One, a 66-year-old male veteran and another 76-year-old male veteran. Both of these cases hold significance as the patient's psychotic depression was so severe as to warrant ECT as a possible treatment. In both cases, this medication combination was able to avoid the procedure. Overall, with the addition of our cases and the sparse information available in the literature, we propose the combination of fluoxetine and olanzapine as an effective Cotard syndrome treatment.

2.
J Psychiatr Pract ; 27(6): 483-485, 2021 11 05.
Article in English | MEDLINE | ID: mdl-34768273

ABSTRACT

Depression is common in patients after liver transplantation and, when severe, can threaten both viability of the graft and the patient's life. Electroconvulsive therapy (ECT) is a safe and highly effective therapy for severe depression, but there have been very few reports of its use in liver transplant recipients. We describe a patient who had undergone a successful orthotopic liver transplant 26 years previously, who developed severe major depression. The patient tolerated an index course of ECT well and responded robustly. There were no complications pertinent to the graft or otherwise. Liver transplantation is not a contraindication to ECT, and clinicians should not hesitate to proceed when necessary.


Subject(s)
Depressive Disorder, Major , Electroconvulsive Therapy , Liver Transplantation , Depressive Disorder, Major/therapy , Humans , Treatment Outcome
3.
Clin Neuropharmacol ; 44(1): 33-34, 2021.
Article in English | MEDLINE | ID: mdl-33201007

ABSTRACT

OBJECTIVES: To examine the effectiveness of low-dose lithium carbonate for managing carbamazepine-induced hyponatremia. METHODS: Single case study in an 88 year old man with bipolar illness and vascular dementia who had failed to respond to other mood stabilizers. RESULTS: The patient had developed hyponatremia on two separate occasions when treated with carbamazepine. Introduction of low-dose lithium resulted in prompt normalization of serum sodium levels, which was maintained for the subsequent 8 weeks. CONCLUSIONS: Carbamazepine may sometimes be the best or only viable treatment option for patients with bipolar illness or other conditions. When its use is complicated by syndrome of inappropriate ADH, dose reduction and fluid restriction are the simplest options but, if ineffective, addition of lithium may be a feasible, albeit somewhat complicated, alternative.


Subject(s)
Antidepressive Agents/administration & dosage , Antimanic Agents/adverse effects , Carbamazepine/adverse effects , Inappropriate ADH Syndrome/chemically induced , Inappropriate ADH Syndrome/drug therapy , Lithium Carbonate/administration & dosage , Aged, 80 and over , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Drug Therapy, Combination , Humans , Inappropriate ADH Syndrome/diagnosis , Male
5.
Curr Drug Saf ; 15(2): 156-159, 2020.
Article in English | MEDLINE | ID: mdl-32096747

ABSTRACT

BACKGROUND: Lamotrigine is a phenyltriazine medication that has been approved by the United States Food and Drug Administration as monotherapy and as an adjunctive agent for the treatment of seizure disorder. It was later approved by the FDA for the treatment of bipolar disorder. Lamotrigine is generally well tolerated by patients, but some serious symptoms can occur during treatment. These severe side effects include rashes and multi-organ failure. Lamotrigine has also been associated with the development of mental status changes, frequently when used concurrently with other medications that may impact the metabolism of lamotrigine. OBJECTIVE: To present the case of a 65-year-old man being treated with lamotrigine and valproic acid who developed mental status changes after the addition of sertraline to his medication regimen, and to compare this case to existing cases reported in the literature. DISCUSSION: Our case adds to the existing literature by demonstrating that patients may experience adverse medication effects despite lamotrigine levels that are normally considered to be in the therapeutic range, highlighting the importance of clinical correlation when obtaining medication levels. CONCLUSION: Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamotrigine toxicity.


Subject(s)
Delirium/chemically induced , Lamotrigine/adverse effects , Lamotrigine/toxicity , Lamotrigine/therapeutic use , Seizures/drug therapy , Adolescent , Adult , Aged , Drug Interactions , Female , Humans , Male , Middle Aged , Sertraline/therapeutic use , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...